Home›Oncology› Node-RADS demonstrates high diagnostic accuracy for lymph node metastasis in rectal cancer patients
Node-RADS demonstrates high diagnostic accuracy for lymph node metastasis in rectal cancer patientsNode-RADS Shows Promise for Detecting Rectal Cancer Lymph Node Spread
Frontiers in MedicinePublished August 27, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that Node-RADS shows high diagnostic accuracy but requires further prospective validation before standalone use.
This systematic review and meta-analysis evaluated the diagnostic accuracy of the Node-RADS imaging system for identifying lymph node metastasis in patients with rectal cancer. The analysis included a total sample size of 994 patients, including 374 with lymph node metastasis and 620 without.
The pooled results indicated a sensitivity of 0.82 (95% CI, 0.74-0.87) and a specificity of 0.84 (95% CI, 0.73-0.91). The diagnostic odds ratio was 23.66 (95% CI, 12.92-43.34), with an SROC AUC of 0.88 (95% CI, 0.85-0.91). When excluding the post-neoadjuvant chemoradiotherapy cohort, sensitivity was 0.79 (95% CI, 0.73-0.84) and specificity was 0.90 (95% CI, 0.84-0.94).
The authors noted several limitations, including substantial heterogeneity among studies, post hoc threshold selection, and a lack of extensive external validation. Furthermore, publication bias could not be excluded due to the small number of included studies. While Node-RADS may serve as a standardized imaging-based adjunct for preoperative nodal assessment, its standalone use requires further prospective validation.
Researchers analyzed data from 994 patients with rectal cancer to test a reporting system called Node-RADS. This system is designed to help doctors use imaging results to determine if cancer has spread to the lymph nodes, which is a critical step in planning treatment.
The analysis found that Node-RADS had a sensitivity of 0.82 and a specificity of 0.84 for identifying lymph node metastasis. These numbers suggest the system can be a helpful tool for doctors during the preoperative stage. However, the study noted some limitations, including differences in how data was collected across different studies and a lack of large-scale testing outside of initial trials.
Because this was a meta-analysis of existing data rather than a new clinical trial, it is not yet ready to replace standard practices. Doctors may use Node-RADS as an extra tool to help interpret scans, but more research is needed to confirm its reliability in everyday practice.
What this means for you:
Node-RADS shows potential as a tool to help identify lymph node involvement in rectal cancer before surgery.
Common questions
What is Node-RADS and how does it work?
Node-RADS is an imaging-based system used to assess lymph nodes in patients with rectal cancer. It helps doctors determine if the cancer has spread before surgery begins. The study found it had a sensitivity of 0.82 and a specificity of 0.84, which means it can be useful as a standardized tool for medical teams.
Is Node-RADS accurate enough to use alone?
The study suggests that while Node-RADS shows promise as an extra tool for doctors, it should not be used alone yet. Because the data came from a meta-analysis with some inconsistencies between studies, more large-scale testing is needed before it can be used as a primary way to make medical decisions.
Who does this finding help?
This finding specifically relates to patients with rectal cancer. It may help their doctors better understand the extent of the cancer through imaging, which helps in planning the most effective treatment and surgery for each individual patient.
ObjectiveTo systematically evaluate the diagnostic accuracy and clinical value of the Node Reporting and Data System (Node-RADS) for lymph node metastasis in rectal cancer (RC).MethodsThe study followed PRISMA-DTA guidelines and was registered in PROSPERO (CRD420261372147). PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang, VIP, and the Chinese Biomedical Literature Database were searched from inception to April 2026. Two reviewers independently screened studies, extracted data, and assessed methodological quality using QUADAS-2. Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the summary receiver operating characteristic (SROC) area under the curve (AUC) were pooled using a bivariate random-effects model. Heterogeneity, publication bias, and clinical utility were assessed using subgroup and sensitivity analyses (including exclusion of the post-neoadjuvant chemoradiotherapy cohort), Deeks’ funnel plot, and Fagan’s nomogram based on the observed prevalence.ResultsSeven studies involving 994 patients with RC were included, comprising 374 with and 620 without lymph node metastasis. Pooled sensitivity, specificity, PLR, NLR, and DOR were 0.82 (95% confidence interval [CI], 0.74-0.87), 0.84 (95% CI, 0.73-0.91), 5.15 (95% CI, 3.06-8.68), 0.22 (95% CI, 0.16-0.30), and 23.66 (95% CI, 12.92-43.34), respectively; the SROC AUC was 0.88 (95% CI, 0.85-0.91). Excluding the clinically distinct post-neoadjuvant chemoradiotherapy study yielded sensitivity of 0.79 (95% CI, 0.73-0.84), specificity of 0.90 (95% CI, 0.84-0.94), and AUC of 0.88 (95% CI, 0.85-0.90), while specificity heterogeneity decreased from 89.07% to 69.79%. At the observed prevalence of 37.6%, a positive Node-RADS result increased the post-test probability to approximately 76%, whereas a negative result reduced it to approximately 12%. No significant funnel-plot asymmetry was detected, although publication bias could not be excluded because only seven studies were included.ConclusionNode-RADS shows good diagnostic accuracy and clinical discriminatory ability for lymph node metastasis in RC and may serve as a standardized imaging-based adjunct for preoperative nodal assessment. However, substantial heterogeneity, post hoc threshold selection, and limited external validation indicate that standalone use requires further prospective validation.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/View/CRD420261372147, identifier CRD420261372147.
